Special Issue

Prebiotics and Probiotics for Health Promotion

Message from the Guest Editors

In recent years, there has been an increased interest in the scientific community concerning the microbiota and its relationship with health and disease. Studies regarding the therapeutic potential of restoring dysbiosis as a treatment for common diseases have shown that the administration of prebiotics and probiotics, in combination or separately, is both simple and accessible. Many researchers have demonstrated the effectiveness of pre- and pro-biotics in promoting health or treating certain morbidities (i.e., COVID-19, H. pylori infection, vaginosis, etc.); however, concerns have been raised regarding the possible risks of administrating probiotics. Prebiotics are simple nutrients that, when degraded by the gut microbiota, produce metabolic molecules that act locally, regulating the microbial communities, or can enter into the bloodstream, reaching distant tissues and affecting their physiology. This Special Issue aims to promote the research and discussion regarding the current knowledge of probiotics/prebiotics, their potential clinical applications, and their possible side effects.

Guest Editors

Dr. Luigi Santacroce

 Interdisciplinary Department of Medicine, Section of Microbiology and Virology, School of Medicine, University of Bari, 70124 Bari, Italy
 Microbiology and Virology Unit, Policlinico University, Rome, Italy

Dr. Lucrezia Bottalico

Polypheno Academic Spin Off, University of Bari "Aldo Moro", 70121 Bari, Italy

Deadline for manuscript submissions

closed (15 October 2022)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/123337

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +4161 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).